Johnson & Johnson Family of Companies

NEWS

Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact

Policy

Johnson & Johnson Falls as FDA Staffers Back Celltrion’s Remicade Biosimilar

February 8, 2016

·

3 min read

Biotech Bay

Will Johnson & Johnson’s Plan To Retool Its Medical Device Business Succeed?

January 29, 2016

·

1 min read

Biopharma Business Grad Hiring Is Up, with Johnson & Johnson, Eli Lilly and Bayer and Genentech Leading the Way

Job Trends

Biopharma Business Grad Hiring Is Up, with Johnson & Johnson, Eli Lilly, Bayer and Genentech Leading the Way

January 25, 2016

·

3 min read

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations

Drug Development

Johnson & Johnson Halts Trial of Drug Similar to One Linked to Brain Dead Tragedy in France

January 22, 2016

·

2 min read

Job Trends

Johnson & Johnson to Chop Up to 6% of Medical Device Workforce in Shakeup

January 19, 2016

·

2 min read

Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact

Business

Big Shot Biotechs Like Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie Bet $48 Million on Startup Petra Pharma

January 6, 2016

·

2 min read

Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact

Deals

Johnson & Johnson May Seek to Divest Itself of Noramco for $800 Million

January 5, 2016

·

2 min read

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations

Biotech Bay

Analyzing Gilead’s Gamble on a Drug Both AbbVie and Johnson & Johnson Gave Up On

December 31, 2015

·

3 min read

Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact

Deals

Analysts Tune Their Crystal Balls to 2016 M&A Prospects, Including Johnson & Johnson, Amgen, Biogen, Sanofi and Others

December 11, 2015

·

3 min read

AWARDS

JOBS

IN THE PRESS

Press Releases

Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies

December 29, 2025

·

5 min read

Press Releases

European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

December 22, 2025

·

14 min read

Press Releases

Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma

December 19, 2025

·

6 min read

Press Releases

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

December 18, 2025

·

33 min read

Press Releases

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025

December 16, 2025

·

1 min read

Press Releases

Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors

December 16, 2025

·

4 min read

Press Releases

U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*

December 15, 2025

·

20 min read

Press Releases

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

December 10, 2025

·

18 min read

Press Releases

Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma

December 10, 2025

·

28 min read

Press Releases

Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 9, 2025

·

1 min read